New Study Links Genes to Pancreatic Cancer Risk and Prognosis

A significant breakthrough in cancer research has emerged from the National Cancer Research Center (CNIO), where scientists have identified multiple gene sets that may influence an individual’s predisposition to pancreatic ductal adenocarcinoma, the most prevalent form of pancreatic cancer. This study, published in Nature Communications, highlights the potential for developing effective screening programs aimed at facilitating early diagnosis, a critical step given the disease’s high mortality rates associated with late detection.

Led by researchers Núria Malats and Evangelina López de Maturana from the Epidemiology and Molecular Genetics Group at CNIO, the research sheds light on the genetic factors that could play a pivotal role in both the onset and prognosis of pancreatic cancer. The challenge of early diagnosis remains daunting, as the disease typically manifests in advanced stages, complicating treatment options.

The study reveals that specific genes related to the body’s complement system—an innate defense mechanism—are linked to the risk of developing pancreatic cancer. When the proteins produced by this system are either deficient or excessively produced, it can lead to disease. Until now, research connecting the complement system to cancer has been limited.

Discovering Potential Biomarkers for Screening

The first author of the study, Alberto Langtry, who is currently affiliated with Columbia University after completing his doctoral thesis at CNIO, has identified mutations in two particular genes, FCN1 and PLAT, as key indicators of increased cancer risk. These genes could serve as useful biomarkers for screening high-risk populations, potentially allowing individuals to participate in monitoring programs. Such initiatives are essential for early intervention in pancreatic cancer, which has one of the highest mortality rates in oncology.

Identifying those at heightened risk is crucial, as it enables healthcare providers to implement targeted screening strategies. According to the authors, this research significantly enhances the understanding of pancreatic cancer susceptibility and can inform future clinical practices.

Implications for Treatment and Immunotherapy

In addition to identifying risk factors, the study explores the role of complement system genes in influencing immune cell behavior within tumors. The researchers discovered that the activity of certain gene groups affects the infiltration of two types of immune cells: defenders and regulators. While defender cells contribute to improved cancer survival, regulatory cells tend to inhibit effective immune responses against tumors.

This research also emphasizes the unique characteristics of pancreatic cancer, often described as a “cold” cancer due to its ability to evade detection by the immune system. This evasion mechanism explains why conventional immunotherapy has largely been ineffective against this form of cancer.

With insights gained from this study, there is potential to develop novel immunotherapies that target the complement system genes identified. Núria Malats noted, “This new knowledge allows us to consider new immunotherapies targeted at these genes,” highlighting a promising avenue for future treatment strategies.

The findings from this research not only pave the way for enhanced screening and diagnostic measures but also open new doors for therapeutic approaches to combat pancreatic cancer, underscoring the importance of ongoing research in this challenging field.

For further details, refer to the original study: Langtry, A. et al. (2025). Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Nature Communications. DOI: 10.1038/s41467-025-65811-y.